









BREAST CANCER - NO WGD  
2323 samples - 14.97 % of the cohort (P: 1256 - 54.1 % | M: 1067 - 45.9 %)  
1454 samples with TP53 hits - 62.59 % (P: 740 - 50.9 % | M: 714 - 49.1 %)







NON-SMALL CELL LUNG CANCER - NO WGD  
1775 samples - 11.44 % of the cohort (P: 1232 - 69.4 % | M: 543 - 30.6 %)  
1009 samples with TP53 hits - 56.85 % (P: 643 - 63.7 % | M: 366 - 36.3 %)












COLORECTAL CANCER - NO WGD  
1448 samples - 9.33 % of the cohort (P: 1071 - 74.0 % | M: 377 - 26.0 %)  
1056 samples with TP53 hits - 72.93 % (P: 763 - 72.3 % | M: 293 - 27.7 %)



GLIOMA - NO WGD



1188 samples - 7.66 % of the cohort (P: 1110 - 93.4 % | M: 78 - 6.6 %)

434 samples with TP53 hits - 36.53 % (P: 408 - 94.0 % | M: 26 - 6.0 %)








PROSTATE CANCER - NO WGD  
1023 samples - 6.59 % of the cohort (P: 590 - 57.7 % | M: 433 - 42.3 %)  
495 samples with TP53 hits - 48.39 % (P: 253 - 51.1 % | M: 242 - 48.9 %)



PANCREATIC CANCER - NO WGD





849 samples - 5.47 % of the cohort (P: 467 - 55.0 % | M: 382 - 45.0 %)

632 samples with TP53 hits - 74.44 % (P: 342 - 54.1 % | M: 290 - 45.9 %)





SKIN CANCER, NON-MELANOMA - NO WGD  
128 samples - 0.83 % of the cohort (P: 64 - 50.0 % | M: 64 - 50.0 %)  
80 samples with TP53 hits - 62.5 % (P: 39 - 48.8 % | M: 41 - 51.2 %)







ENDOMETRIAL CANCER - NO WGD  
652 samples - 4.2 % of the cohort (P: 456 - 69.9 % | M: 196 - 30.1 %)  
243 samples with TP53 hits - 37.27 % (P: 169 - 69.5 % | M: 74 - 30.5 %)
















HEPATOBIILIARY CANCER - NO WGD  
499 samples - 3.22 % of the cohort (P: 365 - 73.1 % | M: 134 - 26.9 %)  
238 samples with TP53 hits - 47.7 % (P: 168 - 70.6 % | M: 70 - 29.4 %)






**BLADDER CANCER - NO WGD**  
**497 samples - 3.2 % of the cohort (P: 396 - 79.7 % | M: 101 - 20.3 %)**  
**263 samples with TP53 hits - 52.92 % (P: 204 - 77.6 % | M: 59 - 22.4 %)**









RENAL CELL CARCINOMA - NO WGD  
451 samples - 2.91 % of the cohort (P: 303 - 67.2 % | M: 148 - 32.8 %)  
138 samples with TP53 hits - 30.6 % (P: 88 - 63.8 % | M: 50 - 36.2 %)














SOFT TISSUE SARCOMA - NO WGD  
437 samples - 2.82 % of the cohort (P: 261 - 59.7 % | M: 176 - 40.3 %)  
177 samples with TP53 hits - 40.5 % (P: 110 - 62.1 % | M: 67 - 37.9 %)









**CANCER OF UNKNOWN PRIMARY - NO WGD**  
**433 samples - 2.79 % of the cohort (P: 48 - 11.1 % | M: 385 - 88.9 %)**  
**255 samples with TP53 hits - 58.89 % (P: 27 - 10.6 % | M: 228 - 89.4 %)**



OVARIAN CANCER - NO WGD




331 samples - 2.13 % of the cohort (P: 151 - 45.6 % | M: 180 - 54.4 %)

231 samples with TP53 hits - 69.79 % (P: 97 - 42.0 % | M: 134 - 58.0 %)








**GASTROINTESTINAL STROMAL TUMOR - NO WGD**  
**329 samples - 2.12 % of the cohort (P: 201 - 61.1 % | M: 128 - 38.9 %)**  
**63 samples with TP53 hits - 19.15 % (P: 27 - 42.9 % | M: 36 - 57.1 %)**







THYROID CANCER - NO WGD  
300 samples - 1.93 % of the cohort (P: 121 - 40.3 % | M: 179 - 59.7 %)  
82 samples with TP53 hits - 27.33 % (P: 37 - 45.1 % | M: 45 - 54.9 %)














ESOPHAGOGASTRIC CANCER - NO WGD  
273 samples - 1.76 % of the cohort (P: 210 - 76.9 % | M: 63 - 23.1 %)  
213 samples with TP53 hits - 78.02 % (P: 163 - 76.5 % | M: 50 - 23.5 %)



**119 samples with TP53 hits - 50.21 % (P: 62 - 52.1 % | M: 57 - 47.9 %)**












MESOTHELIOMA - NO WGD

157 samples - 1.01 % of the cohort (P: 131 - 83.4 % | M: 26 - 16.6 %)

58 samples with TP53 hits - 36.94 % (P: 46 - 79.3 % | M: 12 - 20.7 %)








NON-SMALL CELL LUNG CANCER - NO WGD  
1775 samples - 11.44 % of the cohort (P: 1232 - 69.4 % | M: 543 - 30.6 %)  
1009 samples with TP53 hits - 56.85 % (P: 643 - 63.7 % | M: 366 - 36.3 %)










**SALIVARY GLAND CANCER - NO WGD**  
**137 samples - 0.88 % of the cohort (P: 36 - 26.3 % | M: 101 - 73.7 %)**  
**46 samples with TP53 hits - 33.58 % (P: 12 - 26.1 % | M: 34 - 73.9 %)**







CERVICAL CANCER - NO WGD  
134 samples - 0.86 % of the cohort (P: 80 - 59.7 % | M: 54 - 40.3 %)  
48 samples with TP53 hits - 35.82 % (P: 30 - 62.5 % | M: 18 - 37.5 %)









SKIN CANCER, NON-MELANOMA - NO WGD  
128 samples - 0.83 % of the cohort (P: 64 - 50.0 % | M: 64 - 50.0 %)  
80 samples with TP53 hits - 62.5 % (P: 39 - 48.8 % | M: 41 - 51.2 %)








**BONE CANCER - NO WGD**  
**115 samples - 0.74 % of the cohort (P: 63 - 54.8 % | M: 52 - 45.2 %)**  
**50 samples with TP53 hits - 43.48 % (P: 30 - 60.0 % | M: 20 - 40.0 %)**





UTERINE SARCOMA - NO WGD  
105 samples - 0.68 % of the cohort (P: 41 - 39.0 % | M: 64 - 61.0 %)  
57 samples with TP53 hits - 54.29 % (P: 25 - 43.9 % | M: 32 - 56.1 %)



MATURE B-CELL NEOPLASMS - NO WGD  
102 samples - 0.66 % of the cohort (P: 95 - 93.1 % | M: 7 - 6.9 %)  
42 samples with TP53 hits - 41.18 % (P: 40 - 95.2 % | M: 2 - 4.8 %)

